Amarin Corp. provided an update, noting that the company is increasing revenue guidance for 2019 and is planning to expand the sales force for Vascepa due to faster-than-expected growth.
FDA approves expanded label for Praluent
"Bad" LDL Cholesterol, Approvals, Biotech, Cardiovascular Events, Cholesterol, Drug Pricing, Expanded Label, FDA, FDA/Regulatory, Heart Attacks, Heterozygous Familial Hypercholesterolemia (HeFH), Injectables, Major Adverse Cardiovascular Events (MACE), PCSK9 inhibitors, Statins, StrokeThe U.S. Food and Drug Administration approved Regeneron Pharmaceuticals’ cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.
Sanofi and Regeneron cutting list price of cholesterol drug by 60 percent
"Bad" LDL Cholesterol, Biotech, Cholesterol, Congress, Consumers, Costs, Democrats, Donald Trump, Health Insurers, Heart Attacks, House of Representatives, Injectables, Patients, PCSK9 inhibitors, Pricing, Senate, TherapeuticsSanofi SA and Regeneron Pharmaceuticals Inc. will slash the U.S. list price of the companies’ potent but expensive cholesterol fighter Praluent by 60 percent.
Updated U.S. guidelines on heart health advise more personalized assessment of risk as well as two newer types of cholesterol-lowering drugs for people at particularly high risk of heart attack or stroke.
Esperion’s Bemopedoic Acid Treatments Hit the Mark in Two Studies
"Bad" LDL Cholesterol, Atherosclerotic Cardiovascular Disease (ASCVD), Clinical Data, Clinical Studies, Clinical Trials, European Society of Cardiology (ESC) Congress, FDA, Marketing Authorization Applications, New Drug Applications, R&D, StatinsAnn Arbor, Mich.-based Esperion Therapeutics reported final results from a long-term safety study of bempedoic acid 180 mg versus placebo in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) whose disease is inadequately controlled by statins.
Healthy adults who do not keep their LDL-C, or “bad cholesterol,” in check are more likely to die prematurely from cardiovascular disease than peers with lower cholesterol levels, a U.S. study suggests.
Esperion Therapeutics Inc. said a late-stage trial of the company’s experimental oral drug met the main goal of reducing cholesterol by 28 percent in patients suffering from, or at a high risk of, an artery-clogging heart disease.
Older men may face a premature death if they spend most of the day sitting around, but it does not require a huge amount of exercise to increase their chances of living longer, a study in the UK suggests.
Compared to inactive people, recreational soccer players have lower cholesterol, blood pressure and resting heart rates as well as less fat mass, a research review suggests.
Amgen’s PSCK9 inhibitor Repatha continues to impress as a treatment for patients with peripheral artery disease (PAD) and a history of heart attacks. New data shows Repatha hit its primary endpoints and significantly reduced first-time cardiovascular events by 27 percent in PAD patients.
